

Rajiv Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1607628/publications.pdf>

Version: 2024-02-01

407
papers

27,502
citations

6840

81
h-index

8878

150
g-index

436
all docs

436
docs citations

436
times ranked

17981
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of the COMbinatioN effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrology Dialysis Transplantation, 2023, 38, 894-903.	0.4	48
2	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrology Dialysis Transplantation, 2022, 37, 1014-1023.	0.4	50
3	NIH Funding, Research Productivity, and Scientific Impact: a 20-Year Study. Journal of General Internal Medicine, 2022, 37, 104-109.	1.3	2
4	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	2.1	23
5	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLPâ€RA</sc> treatment: A subgroup analysis from the <sc>FIDELIOâ€DKD</sc> trial. Diabetes, Obesity and Metabolism, 2022, 24, 125-134.	2.2	41
6	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports, 2022, 7, 36-45.	0.4	73
7	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal, 2022, 43, 474-484.	1.0	341
8	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology: JASN, 2022, 33, 225-237.	3.0	89
9	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology Dialysis Transplantation, 2022, 37, 1261-1269.	0.4	32
10	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation, 2022, 145, 437-447.	1.6	86
11	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 361-373.	2.2	9
12	Moderating Effects in Randomized Trialsâ€Interpreting the Pâ€Value, Confidence Intervals, and Hazard Ratios. Kidney International Reports, 2022, 7, 371-374.	0.4	4
13	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 2022, 45, e888-e897.	4.3	20
14	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
15	Emerging Role of Clinical Genetics in CKD. Kidney Medicine, 2022, 4, 100435.	1.0	12
16	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIOâ€DKD</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	2.9	23
17	Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15â€%000 individuals. Diabetes, Obesity and Metabolism, 2022, 24, 1390-1393.	2.2	0
18	Spirolactone and chlorthalidoneâ€old drugs, new usesâ€but approach with caution. Nephrology Dialysis Transplantation, 2022, 37, 407-408.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
20	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. <i>Diabetes Care</i> , 2022, 45, 1445-1452.	4.3	18
21	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
22	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	3
23	Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.	2.6	112
24	Management of hypertension in advanced kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 374-379.	1.0	0
25	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20
26	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
27	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
28	Can We Study Hypertension in Patients on Dialysis? Yes We Can. <i>American Journal of Kidney Diseases</i> , 2021, 77, 4-6.	2.1	6
29	Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets. <i>American Journal of Hypertension</i> , 2021, 34, 318-326.	1.0	16
30	Refractory Hypertension and Kidney Failure. <i>Hypertension</i> , 2021, 77, 82-84.	1.3	2
31	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	1.0	249
32	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	1.2	9
33	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
34	Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2000-2007.	0.4	11
35	Should renin-angiotensin-aldosterone system inhibition enablement be a therapeutic target in CKD patients?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1771-1772.	0.4	0
36	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 384, 1601-1612.	13.9	106
38	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
39	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
40	Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1407-1409.	2.2	5
41	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
42	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1742-1767.	0.3	82
43	Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e053019.	0.8	10
44	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
45	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
46	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
47	Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". <i>Circulation</i> , 2021, 144, e202-e203.	1.6	7
48	Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 2281-2291.	0.4	33
49	Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial. <i>Kidney360</i> , 2021, 2, 425-434.	0.9	13
50	Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 385, 2507-2519.	13.9	139
51	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	1.4	15
52	Beta-blockers in heart failure patients with severe chronic kidney disease—time for a randomized controlled trial?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 728-731.	0.4	1
53	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c $\leq 7\%$. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
54	Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes: Ready for Prime Time?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 1-3.	2.1	144

#	ARTICLE	IF	CITATIONS
55	Cardiorenal protection in advanced chronic kidney disease: research highlights from landmark papers published in <i>Nephrology Dialysis Transplantation</i> during 2018. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 375-378.	0.4	0
56	Much to Fear about MUCH. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2496-2499.	3.0	1
57	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
58	Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial. <i>American Journal of Nephrology</i> , 2020, 51, 542-552.	1.4	10
59	Effects of Canagliflozin in Patients with Baseline eGFR \leq 30 ml/min per 1.73 m ² . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
60	Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER Authors' reply. <i>Lancet, The</i> , 2020, 396, 311-312.	6.3	0
61	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020, 2, 639-649.	1.0	45
62	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	13.9	1,148
63	Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda. <i>Current Hypertension Reports</i> , 2020, 22, 84.	1.5	20
64	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
65	Can We Mend the Broken Clock by Timing Antihypertensive Therapy Sensibly?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1513-1515.	2.2	6
66	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1462-1471.	2.9	27
67	SO033PATIROMER TO ENABLE SPIRONOLACTONE IN PATIENTS WITH RESISTANT HYPERTENSION AND CHRONIC KIDNEY DISEASE (AMBER): PRESPECIFIED RESULTS BY BASELINE SERUM POTASSIUM. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
68	Research Priorities for Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 1001-1026.	1.6	239
69	Spironolactone for resistant hypertension in advanced chronic kidney disease—red, amber or green?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1288-1290.	0.4	0
70	Left Ventricular Mass and Incident Chronic Kidney Disease. <i>Hypertension</i> , 2020, 75, 702-706.	1.3	13
71	Ambulatory BP Phenotypes and Their Association with Target Organ Damage and Clinical Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 441-443.	2.2	2
72	Home Blood Pressure Monitoring in Children, Pregnancy, and Chronic Kidney Disease. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 131-141.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Antihypertensive Therapy in Patients Receiving Maintenance Hemodialysis: A Narrative Review of the Available Clinical-Trial Evidence. <i>Current Vascular Pharmacology</i> , 2020, 19, 12-20.	0.8	2
74	Kidney parenchymal hypertension. , 2019, , 438-443.		0
75	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
76	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
77	Caring for individuals with hypertension in CKD, especially those with low education. <i>Kidney International</i> , 2019, 96, 820-822.	2.6	3
78	Systolic and diastolic hypertension among patients on hemodialysis: Musings on volume overload, arterial stiffness, and erythropoietin. <i>Seminars in Dialysis</i> , 2019, 32, 507-512.	0.7	7
79	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
80	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 1540-1550.	6.3	231
81	Intravenous Iron and Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, e46.	13.9	2
82	Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide. <i>Diabetes Care</i> , 2019, 42, 693-700.	4.3	74
83	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	2.1	24
84	Systolic Blood Pressure Intervention Trial and Statins, a Story of Statistical Interaction. <i>American Journal of Nephrology</i> , 2019, 49, 294-296.	1.4	0
85	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
86	Review: Automated office BP measures are similar to awake ambulatory BP and lower than other office BP measures. <i>Annals of Internal Medicine</i> , 2019, 170, JC69.	2.0	3
87	Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, $\hat{1}^2$ -blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1216-1222.	0.4	4
88	Glomerular filtration rate: when to measure and in which patients?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2001-2007.	0.4	26
89	Hypertension in chronic kidney disease:Nephrology Dialysis Transplantationnotable 2017 advances. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1-4.	0.4	31
90	Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 757-764.	2.2	76

#	ARTICLE	IF	CITATIONS
91	Rehospitalization Rates in Hypertensive Emergency. <i>Hypertension</i> , 2019, 73, 49-51.	1.3	5
92	Assessment and Management of Hypertension among Patients on Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 297-305.	2.2	37
93	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	1.0	34
94	Prevention of intradialytic hypotensive episodes: is setraline an effective pharmacological approach?. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2019, 41, 445-447.	0.4	1
95	Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1690-1698.	0.4	36
96	Revisiting RAAS blockade in CKD with newer potassium-binding drugs. <i>Kidney International</i> , 2018, 93, 325-334.	2.6	62
97	Big data in nephrology—a time to rethink. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1-3.	0.4	38
98	Feeding during dialysis—risks and uncertainties. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 917-922.	0.4	23
99	Creatinine Bump Following Antihypertensive Therapy. <i>Hypertension</i> , 2018, 72, 1274-1276.	1.3	11
100	Meet the Twins: Intradialytic and Interdialytic Hypertension. <i>American Journal of Nephrology</i> , 2018, 48, 292-294.	1.4	1
101	Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease. <i>Kidney International</i> , 2018, 94, 1199-1204.	2.6	10
102	Patiomer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. <i>American Journal of Nephrology</i> , 2018, 48, 172-180.	1.4	20
103	Blood pressure control in conventional hemodialysis. <i>Seminars in Dialysis</i> , 2018, 31, 557-562.	0.7	11
104	Altered circadian hemodynamic and renal function in cirrhosis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw014.	0.4	3
105	Blood Pressure and Mortality in Long-Term Hemodialysis—Time to Move Forward. <i>American Journal of Hypertension</i> , 2017, 30, hpw114.	1.0	36
106	Albuminuria and masked uncontrolled hypertension in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw325.	0.4	12
107	Delayed systolic blood pressure recovery following exercise as a mechanism of masked uncontrolled hypertension in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw266.	0.4	8
108	Blood pressure is blood pressure is blood pressure: Or is it?. <i>Journal of Clinical Hypertension</i> , 2017, 19, 303-304.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	104
110	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Associationâ€“European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.4	133
111	Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions. <i>Hemodialysis International</i> , 2017, 21, S78-S82.	0.4	14
112	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.3	56
113	Endothelin A receptor antagonists in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 338-344.	1.0	17
114	Glomerular filtration rate estimating equations: practical, yes, but can they replace measured glomerular filtration rate?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 405-407.	0.4	4
115	Diagnosing and managing sleep apnea in patients with chronic cerebrovascular disease: a randomized trial of a home-based strategy. <i>Sleep and Breathing</i> , 2017, 21, 713-725.	0.9	24
116	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2017, 46, 364-370.	1.4	7
117	Blood pressure in hemodialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 523-529.	1.0	8
118	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	3.8	376
119	Modification of Potassium-Mortality Relationship by Ethnicity and Race: Solving the Puzzle. <i>American Journal of Nephrology</i> , 2017, 45, 552-554.	1.4	1
120	Setting the dry weight and its cardiovascular implications. <i>Seminars in Dialysis</i> , 2017, 30, 481-488.	0.7	27
121	What are the Considerations in Balancing Benefits and Risks in Iron Treatment?. <i>Seminars in Dialysis</i> , 2017, 30, 22-25.	0.7	0
122	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDESCENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
123	Iron Use in End-Stage Renal Disease. , 2017, , 576-587.e1.		0
124	Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. <i>American Journal of Nephrology</i> , 2016, 44, 404-410.	1.4	47
125	Home Blood Pressureâ€“Guided Antihypertensive Therapy Requires a Randomized Trial â€“. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1528-1530.	1.2	1
126	Opponentâ€™s comments. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 705-705.	0.4	1

#	ARTICLE	IF	CITATIONS
127	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	1.3	63
128	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	1.3	86
129	Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 31, 706-713.	0.4	59
130	Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nature Reviews Nephrology, 2016, 12, 636-647.	4.1	56
131	Arterial stiffness and its relationship to clinic and ambulatory blood pressure: a longitudinal study in non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 32, gfw281.	0.4	5
132	The natural history of symptomatic cardiac conduction-system disease in end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 31, 1973-1975.	0.4	2
133	Pharmacotherapy of Hypertension in Chronic Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2062-2075.	2.2	30
134	Rest before blood pressure measurement: a lesson from SPRINT. Nature Reviews Nephrology, 2016, 12, 127-128.	4.1	5
135	Longitudinal Study of Left Ventricular Mass Growth. Hypertension, 2016, 67, 710-716.	1.3	14
136	Thiazides are useful agents in CKD. Journal of the American Society of Hypertension, 2016, 10, 288-289.	2.3	9
137	Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess. Nephrology Dialysis Transplantation, 2016, 31, 142-149.	0.4	3
138	Defining end-stage renal disease in clinical trials: a framework for adjudication: Table 1. Nephrology Dialysis Transplantation, 2016, 31, 864-867.	0.4	60
139	Masked Uncontrolled Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 924-932.	3.0	78
140	The Complex Relationship Between CKD and Ambulatory Blood Pressure Patterns. Advances in Chronic Kidney Disease, 2015, 22, 102-107.	0.6	31
141	Pro: Ambulatory blood pressure should be used in all patients on hemodialysis. Nephrology Dialysis Transplantation, 2015, 30, 1432-1437.	0.4	20
142	The Author Replies. Kidney International, 2015, 88, 1446-1447.	2.6	2
143	Thiazide Diuretics in Chronic Kidney Disease. Current Hypertension Reports, 2015, 17, 13.	1.5	31
144	Why Does Renal Resistive Index Predict Mortality in Chronic Kidney Disease?. Hypertension, 2015, 66, 267-269.	1.3	3

#	ARTICLE	IF	CITATIONS
145	Adverse Effects of Conventional Thrice-Weekly Hemodialysis: Is It Time to Avoid 3-Day Interdialytic Intervals?. <i>American Journal of Nephrology</i> , 2015, 41, 400-408.	1.4	41
146	A randomized trial of intravenous and oral iron in chronic kidney disease. <i>Kidney International</i> , 2015, 88, 905-914.	2.6	152
147	BP Components in Advanced CKD and the Competing Risks of Death, ESRD, and Cardiovascular Events. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 911-913.	2.2	2
148	What are the Consequences of Volume Expansion in Chronic Dialysis Patients?. <i>Seminars in Dialysis</i> , 2015, 28, 231-232.	0.7	4
149	Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2015, 66, 305-312.	2.1	22
150	Effect of Lisinopril and Atenolol on Aortic Stiffness in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 639-645.	2.2	24
151	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	3.8	523
152	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1441-1442.	0.4	1
153	What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?. <i>Current Cardiology Reports</i> , 2015, 17, 101.	1.3	9
154	Thiazides in advanced chronic kidney disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 366-372.	0.8	14
155	Relative Importance of Aortic Stiffness and Volume as Predictors of Treatment-Induced Improvement in Left Ventricular Mass Index in Dialysis. <i>PLoS ONE</i> , 2015, 10, e0135457.	1.1	8
156	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	1.4	33
157	Introduction: Resistant Hypertension. <i>Seminars in Nephrology</i> , 2014, 34, 481-482.	0.6	0
158	What are the Causes of the Ill Effects of Chronic Hemodialysis?. <i>Seminars in Dialysis</i> , 2014, 27, 11-13.	0.7	4
159	Chlorthalidone for Poorly Controlled Hypertension in Chronic Kidney Disease: An Interventional Pilot Study. <i>American Journal of Nephrology</i> , 2014, 39, 171-182.	1.4	81
160	Review of blood pressure control rates and outcomes. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 127-141.	2.3	55
161	Assessment and Management of Hypertension in Patients on Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1630-1646.	3.0	134
162	Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 672-681.	0.4	193

#	ARTICLE	IF	CITATIONS
163	Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter Prospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2014, 64, 744-752.	2.1	96
164	A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2293-2302.	0.4	61
165	Hypertension Treatment for Patients with Advanced Chronic Kidney Disease. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	4
166	Hypertension and Chronic Kidney Disease. , 2014, , 57-69.		0
167	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
168	Chronic Renal Disease Progression: Treatment Strategies and Potassium Intake. <i>Seminars in Nephrology</i> , 2013, 33, 290-299.	0.6	19
169	Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 236-243.	2.3	16
170	Salt, Salt Sensitivity, and the Endothelium. <i>Hypertension</i> , 2013, 62, 831-833.	1.3	1
171	B-type natriuretic peptide is not a volume marker among patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3082-3089.	0.4	41
172	KDIGO BP guidelinesâ€”more individualized, less prescriptive. <i>Nature Reviews Nephrology</i> , 2013, 9, 131-133.	4.1	4
173	Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 612-622.	2.1	119
174	Ambulatory Blood Pressure Monitoring Trumps Estimated Glomerular Filtration Rate in Predicting Cardiovascular Risk in Low-Risk Populations. <i>Hypertension</i> , 2013, 61, 14-15.	1.3	1
175	Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2461-2467.	1.2	139
176	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 201-213.	2.1	174
177	Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1562-1568.	0.4	23
178	Renal Failure in Cirrhosis: Is It Time to Change the Diagnosis and Classification?. <i>American Journal of Nephrology</i> , 2013, 38, 342-344.	1.4	2
179	Use of Dried Plasma Spots for the Quantification of Iothalamate in Clinical Studies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 909-914.	2.2	19
180	What Can We Learn from Null Randomized Controlled Trials?. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 691-693.	3.0	3

#	ARTICLE	IF	CITATIONS
181	Blood pressure response with fixed-dose combination therapy. Journal of Hypertension, 2013, 31, 1692-1701.	0.3	6
182	Volume Overload in Dialysis: The Elephant in the Room, No One Can See. American Journal of Nephrology, 2013, 38, 75-77.	1.4	26
183	Subgroup Analyses in Nephrology Clinical Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1872-1876.	2.2	6
184	Patients on three times-weekly haemodialysis have increased mortality during the long, 2-day interdialytic interval. Evidence-Based Medicine, 2012, 17, 161-162.	0.6	0
185	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2012, 307, 674.	3.8	495
186	How can we prevent intradialytic hypotension?. Current Opinion in Nephrology and Hypertension, 2012, 21, 593-599.	1.0	67
187	Response to Body Mass Index-Mortality Paradox in Hemodialysis: Can It Be Explained by Blood Pressure?. Hypertension, 2012, 59, .	1.3	1
188	Multiple comparisons, interaction effects, and statistical inference: lessons from chronic kidney disease progression among blacks. Kidney International, 2012, 81, 516-519.	2.6	1
189	Determinants and Short-Term Reproducibility of Relative Plasma Volume Slopes during Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1996-2001.	2.2	11
190	Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. Nephrology Dialysis Transplantation, 2012, 27, 310-317.	0.4	7
191	Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 3908-3914.	0.4	122
192	Use of ð%¥Â1 antihypertensive drug at bedtime reduced CV events more than use of all drugs in the morning in CKD. Annals of Internal Medicine, 2012, 156, JC6.	2.0	1
193	Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrology Dialysis Transplantation, 2012, 27, 4041-4045.	0.4	27
194	Thiazide diuretics in advanced chronic kidney disease. Journal of the American Society of Hypertension, 2012, 6, 299-308.	2.3	72
195	Thiazide and Thiazide-Like Diuretics. Hypertension, 2012, 59, 1089-1090.	1.3	0
196	The Controversies of Diagnosing and Treating Hypertension among Hemodialysis Patients. Seminars in Dialysis, 2012, 25, 370-376.	0.7	16
197	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American Heart Journal, 2012, 164, 902-909.e2.	1.2	112
198	Renal parenchymal hypertension. , 2012, , 444-449.		0

#	ARTICLE	IF	CITATIONS
199	Diagnosis and Treatment of Sleep Apnea in Patients' Homes: The Rationale and Methods of the "GoToSleep" Randomized-Controlled Trial. <i>Journal of Clinical Sleep Medicine</i> , 2012, 08, 27-35.	1.4	19
200	Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. <i>Kidney International</i> , 2011, 80, 1073-1079.	2.6	70
201	Frequent versus Standard Hemodialysis. <i>New England Journal of Medicine</i> , 2011, 364, 974-976.	13.9	7
202	Role of Home Blood Pressure Monitoring in Overcoming Therapeutic Inertia and Improving Hypertension Control. <i>Hypertension</i> , 2011, 57, 29-38.	1.3	342
203	Interdialytic Hypertension—An Update. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 11-16.	0.6	6
204	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. <i>Clinical Trials</i> , 2011, 8, 165-174.	0.7	20
205	Relationship between Glycosylated Hemoglobin and Blood Glucose during Progression of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 32-41.	1.4	16
206	Blood pressure goal in chronic kidney disease: what is the evidence?. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 229-232.	1.0	9
207	Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk?. <i>Current Hypertension Reports</i> , 2011, 13, 192-199.	1.5	23
208	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. <i>Kidney International Supplements</i> , 2011, 1, 6-9.	4.6	57
209	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. <i>Kidney International Supplements</i> , 2011, 1, 17-20.	4.6	9
210	Patterns and Prognostic Value of Total and Differential Leukocyte Count in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1393-1399.	2.2	46
211	Body Mass Index-Mortality Paradox in Hemodialysis. <i>Hypertension</i> , 2011, 58, 1014-1020.	1.3	27
212	Management of anaemia in CKD—the relative importance of erythropoietin and iron. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i1-i2.	1.4	0
213	Sleep and Activity in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1258-1265.	2.2	69
214	Prognostic Role of Ambulatory Blood Pressure Measurement in Patients With Nondialysis Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1090-8.	4.3	256
215	Probing Dry-Weight Improves Left Ventricular Mass Index. <i>American Journal of Nephrology</i> , 2011, 33, 373-380.	1.4	39
216	Epidemiology of Interdialytic Ambulatory Hypertension and the Role of Volume Excess. <i>American Journal of Nephrology</i> , 2011, 34, 381-390.	1.4	81

#	ARTICLE	IF	CITATIONS
217	Chronic Kidney Disease as a Coronary Disease Equivalent—A Comparison with Diabetes over a Decade. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1385-1392.	2.2	47
218	Proteinuria Induced by Parenteral Iron in Chronic Kidney Disease—A Comparative Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 114-121.	2.2	25
219	Proteinuria and hypertension with tyrosine kinase inhibitors. <i>Kidney International</i> , 2011, 80, 1271-1277.	2.6	67
220	Determinants and Prognostic Significance of Electrocardiographic Left Ventricular Hypertrophy Criteria in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 528-536.	2.2	22
221	Toward a Definition of Masked Hypertension and White-Coat Hypertension among Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2003-2008.	2.2	36
222	Neither Proteinuria Nor Albuminuria Is Associated With Endothelial Dysfunction in HIV-Infected Patients Without Diabetes or Hypertension. <i>Journal of Infectious Diseases</i> , 2011, 204, 1946-1950.	1.9	7
223	Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 33, 139-149.	1.4	36
224	Inferior Vena Cava Diameter and Left Atrial Diameter Measure Volume but Not Dry Weight. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1066-1072.	2.2	69
225	Major pathways of the reno—cardiovascular link: the sympathetic and renin—angiotensin systems. <i>Kidney International Supplements</i> , 2011, 1, 13-16.	4.6	11
226	The complexity of the cardio—renal link: taxonomy, syndromes, and diseases. <i>Kidney International Supplements</i> , 2011, 1, 2-5.	4.6	24
227	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease. <i>Kidney International Supplements</i> , 2011, 1, 10-12.	4.6	44
228	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. <i>Kidney International Supplements</i> , 2011, 1, 21-23.	4.6	37
229	Urine dipstick readings ≥1+ had limited sensitivity but high specificity for detecting albuminuria in adults. <i>Annals of Internal Medicine</i> , 2011, 155, J4.	2.0	3
230	Regulation of circadian blood pressure: from mice to astronauts. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 51-58.	1.0	69
231	Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?. <i>Current Hypertension Reports</i> , 2010, 12, 356-363.	1.5	7
232	Relative Plasma Volume Monitoring for Identifying Volume-Sensitive and -Resistant Hypertension. <i>Seminars in Dialysis</i> , 2010, 23, 462-465.	0.7	11
233	Rebuttal: CON Position. People with Chronic Kidney Disease Should Have a Blood Pressure Lower than 130/80 mm Hg. <i>American Journal of Nephrology</i> , 2010, 32, 379-380.	1.4	3
234	Dry-Weight. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1255-1260.	2.2	137

#	ARTICLE	IF	CITATIONS
235	Relative Plasma Volume Monitoring During Hemodialysis Aids the Assessment of Dry Weight. Hypertension, 2010, 55, 305-311.	1.3	86
236	The Effect of Measuring Ambulatory Blood Pressure on Nighttime Sleep and Daytime Activity—Implications for Dipping. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 281-285.	2.2	60
237	Epidemiology of Chronic Kidney Disease Among Normotensives. Hypertension, 2010, 55, 1097-1099.	1.3	6
238	Median Intradialytic Blood Pressure Can Track Changes Evoked by Probing Dry-Weight. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 897-904.	2.2	17
239	Hypervolemia Is Associated With Increased Mortality Among Hemodialysis Patients. Hypertension, 2010, 56, 512-517.	1.3	128
240	Diagnosing Obesity by Body Mass Index in Chronic Kidney Disease. Hypertension, 2010, 56, 893-900.	1.3	98
241	Individualizing Decision-Making—Resurrecting the Doctor-Patient Relationship in the Anemia Debate. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1340-1346.	2.2	18
242	Blood Pressure and Mortality Among Hemodialysis Patients. Hypertension, 2010, 55, 762-768.	1.3	232
243	Developing a self-administered CKD symptom assessment instrument. Nephrology Dialysis Transplantation, 2010, 25, 160-166.	0.4	25
244	Managing hypertension using home blood pressure monitoring among haemodialysis patients—a call to action. Nephrology Dialysis Transplantation, 2010, 25, 1766-1771.	0.4	40
245	Physical Activity Is a Determinant of Circadian Blood Pressure Variation in Chronic Kidney Disease. American Journal of Nephrology, 2010, 31, 15-23.	1.4	8
246	A longitudinal study of kidney structure and function in adults. Nephrology Dialysis Transplantation, 2010, 25, 1120-1126.	0.4	29
247	Intradialytic hypertension is a marker of volume excess. Nephrology Dialysis Transplantation, 2010, 25, 3355-3361.	0.4	78
248	Debate: CON Position. People with Chronic Kidney Disease Should Have a Blood Pressure Lower than 130/80 mm Hg. American Journal of Nephrology, 2010, 32, 374-376.	1.4	9
249	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	6.3	613
250	Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?. Kidney International, 2010, 77, 943-945.	2.6	19
251	Blood Pressure Components and the Risk for End-Stage Renal Disease and Death in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 830-837.	2.2	102
252	Response to Nighttime Activity Influences the Evaluation of Ambulatory Blood Pressure Monitoring. Hypertension, 2009, 54, .	1.3	0

#	ARTICLE	IF	CITATIONS
253	Response to Meta-Analysis of the Effects of Treating Blood Pressure on Cardiovascular Outcomes of Dialysis Patients. Hypertension, 2009, 54, e7.	1.3	1
254	Cardiovascular Protection With Antihypertensive Drugs in Dialysis Patients. Hypertension, 2009, 53, 860-866.	1.3	191
255	Home Blood Pressure Measurements for Managing Hypertension in Hemodialysis Patients. American Journal of Nephrology, 2009, 30, 126-134.	1.4	62
256	Prognostic Value of Circadian Blood Pressure Variation in Chronic Kidney Disease. American Journal of Nephrology, 2009, 30, 547-553.	1.4	24
257	Circadian Blood Pressure Classification Scheme and the Health of Patients with Chronic Kidney Disease. American Journal of Nephrology, 2009, 30, 536-546.	1.4	18
258	Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP). Hypertension, 2009, 53, 500-507.	1.3	313
259	Volume-Associated Ambulatory Blood Pressure Patterns in Hemodialysis Patients. Hypertension, 2009, 54, 241-247.	1.3	48
260	Nocturia, Nocturnal Activity, and Nondipping. Hypertension, 2009, 54, 646-651.	1.3	70
261	Response to Sympathetic Activity and Clinical Outcome in Dialysis Patients. Hypertension, 2009, 54, .	1.3	0
262	Masked Hypertension and White-Coat Hypertension in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 656-664.	2.2	117
263	Vitamin D, Proteinuria, Diabetic Nephropathy, and Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1523-1528.	2.2	87
264	Assessment of Iothalamate Plasma Clearance. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 77-85.	2.2	53
265	GFR, proteinuria and circadian blood pressure. Nephrology Dialysis Transplantation, 2009, 24, 2400-2406.	0.4	68
266	Chronobiology of Arterial Hypertension in Hemodialysis Patients: Implications for Home Blood Pressure Monitoring. American Journal of Kidney Diseases, 2009, 54, 693-701.	2.1	41
267	Peridialytic, Intradialytic, and Interdialytic Blood Pressure Measurement in Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 54, 788-791.	2.1	21
268	<i>Opinion</i>: Can Chronic Volume Overload Be Recognized and Prevented in Hemodialysis Patients?. Seminars in Dialysis, 2009, 22, 480-482.	0.7	79
269	Hyporesponsiveness to Erythropoietin: Causes and Management. Advances in Chronic Kidney Disease, 2009, 16, 94-100.	0.6	73
270	Out-of-office blood pressure monitoring in chronic kidney disease. Blood Pressure Monitoring, 2009, 14, 2-11.	0.4	65

#	ARTICLE	IF	CITATIONS
271	Home and ambulatory blood pressure monitoring in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 507-512.	1.0	38
272	Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	0
273	Iron, oxidative stress, and clinical outcomes. <i>Pediatric Nephrology</i> , 2008, 23, 1195-1199.	0.9	24
274	Temperature sensitivity and fluorescence detection. <i>Journal of Separation Science</i> , 2008, 31, 128-132.	1.3	6
275	Diagnostic Utility of Blood Volume Monitoring in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2008, 51, 242-254.	2.1	40
276	Serum Albumin Is Strongly Associated with Erythropoietin Sensitivity in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 98-104.	2.2	58
277	Hypertension, Hypokalemia, and Thiazide-Induced Diabetes. <i>Hypertension</i> , 2008, 52, 1012-1013.	1.3	16
278	Location Not Quantity of Blood Pressure Measurements Predicts Mortality in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2008, 28, 210-217.	1.4	67
279	Competing Risk Factor Analysis of End-Stage Renal Disease and Mortality in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2008, 28, 569-575.	1.4	54
280	Analyzing Change: A Primer on Multilevel Models with Applications to Nephrology. <i>American Journal of Nephrology</i> , 2008, 28, 792-801.	1.4	75
281	Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease. <i>Hypertension</i> , 2008, 52, 249-255.	1.3	301
282	Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F303-F308.	1.3	63
283	On the Importance of Pedal Edema in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 153-158.	2.2	118
284	Interpreting Results of Clinical Trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1246-1252.	2.2	8
285	Response to Prognostic Significance of Between-Arm Blood Pressure Differences: Between-Arm Blood Pressure Difference and Mortality and the Interarm Blood Pressure Difference: Between-Arm Blood Pressure Differences Are Important. <i>Hypertension</i> , 2008, 52, .	1.3	0
286	Diagnosing Hypertension by Intradialytic Blood Pressure Recordings. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1364-1372.	2.2	72
287	Physical Activity and Hemodynamic Reactivity in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1660-1668.	2.2	23
288	Prognostic Significance of Between-Arm Blood Pressure Differences. <i>Hypertension</i> , 2008, 51, 657-662.	1.3	94

#	ARTICLE	IF	CITATIONS
289	Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?. Nature Clinical Practice Nephrology, 2008, 4, 418-419.	2.0	2
290	Epoetin and Iron Deficiency. , 2008, , 804-811.		0
291	Author's response to "Comment on "Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?" Nature Clinical Practice Nephrology, 2008, 4, E2-E2.	2.0	0
292	Relationship between circadian blood pressure variation and circadian protein excretion in CKD. American Journal of Physiology - Renal Physiology, 2007, 293, F655-F659.	1.3	22
293	Home BP for assessing haemodialysis hypertension. Nephrology Dialysis Transplantation, 2007, 22, 3089-3090.	0.4	1
294	Proteinuria and Endothelial Dysfunction in Stable HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 596-598.	0.9	7
295	Proteinuria Is a Determinant of Quality of Life in Diabetic Nephropathy: Modeling Lagged Effects with Path Analysis. American Journal of Nephrology, 2007, 27, 488-494.	1.4	14
296	Reproducibility of Renal Function Measurements in Adult Men with Diabetic Nephropathy: Research and Clinical Implications. American Journal of Nephrology, 2007, 27, 92-100.	1.4	24
297	Nonhematological Benefits of Iron. American Journal of Nephrology, 2007, 27, 565-571.	1.4	64
298	Trended Cosinor Change Model for Analyzing Hemodynamic Rhythm Patterns in Hemodialysis Patients. Hypertension, 2007, 50, 143-150.	1.3	47
299	Home Blood Pressures Are of Greater Prognostic Value than Hemodialysis Unit Recordings. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1228-1234.	2.2	212
300	Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension, 2007, 16, 409-415.	1.0	25
301	Dialysis dose and the diagnosis of hypertension in hemodialysis patients. Blood Pressure Monitoring, 2007, 12, 281-287.	0.4	5
302	Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Seminars in Nephrology, 2007, 27, 538-543.	0.6	25
303	Effects of Statins on Renal Function. Mayo Clinic Proceedings, 2007, 82, 1381-1390.	1.4	69
304	Guest Editor: Rajiv Agarwal: How Should Hypertension Be Assessed and Managed in Hemodialysis Patients?. Seminars in Dialysis, 2007, 20, 402-405.	0.7	11
305	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Hypertension Is Harmful to Dialysis Patients and Should Be Controlled. Seminars in Dialysis, 2007, 20, 518-522.	0.7	11
306	Relationships of N-Terminal Pro-B-Natriuretic Peptide and Cardiac Troponin T to Left Ventricular Mass and Function and Mortality in Asymptomatic Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 50, 1009-1019.	2.1	121

#	ARTICLE	IF	CITATIONS
307	Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 92-100.	2.0	10
308	Diabetic kidney disease: pathophysiology, implications and management. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 38-39.	3.1	13
309	Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 309-313.	1.0	17
310	Management of hypertension in hemodialysis patients. <i>Hemodialysis International</i> , 2006, 10, 241-248.	0.4	14
311	Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. <i>Kidney International</i> , 2006, 69, 406-411.	2.6	154
312	Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. <i>Kidney International</i> , 2006, 69, 900-906.	2.6	145
313	Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. <i>Kidney International</i> , 2006, 69, 1175-1180.	2.6	211
314	Effects of Statins on Renal Function. <i>American Journal of Cardiology</i> , 2006, 97, 748-755.	0.7	68
315	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 565-577.	2.1	177
316	Blood Pressure Recordings within and outside the Clinic and Cardiovascular Events in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2006, 26, 503-510.	1.4	109
317	A Randomized Controlled Trial of Oral versus Intravenous Iron in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2006, 26, 445-454.	1.4	107
318	Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F600-F605.	1.3	79
319	Acute Injury with Intravenous Iron and Concerns Regarding Long-Term Safety. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, S19-S23.	2.2	79
320	Out-of-Hemodialysis-Unit Blood Pressure Is a Superior Determinant of Left Ventricular Hypertrophy. <i>Hypertension</i> , 2006, 47, 62-68.	1.3	167
321	Strategies for Successful Patient Oriented Research: Why Did I (not) Get Funded?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 340-343.	2.2	11
322	Benefits of and Barriers to Dietary Sodium Adherence. <i>Western Journal of Nursing Research</i> , 2006, 28, 162-180.	0.6	37
323	Appropriateness of Antihypertensive Drug Therapy in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 820-824.	2.2	16
324	Pre- and Postdialysis Blood Pressures Are Imprecise Estimates of Interdialytic Ambulatory Blood Pressure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 389-398.	2.2	200

#	ARTICLE	IF	CITATIONS
325	The Role of Statins in Chronic Kidney Disease. American Journal of the Medical Sciences, 2005, 330, 69-81.	0.4	21
326	Accuracy of oscillometric blood pressure monitoring with concurrent auscultatory blood pressure in hemodialysis patients. Blood Pressure Monitoring, 2005, 10, 249-255.	0.4	31
327	Hypertension and survival in chronic hemodialysis patients—Past lessons and future opportunities. Kidney International, 2005, 67, 1-13.	2.6	156
328	A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney International, 2005, 68, 285-292.	2.6	63
329	Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International, 2005, 68, 2823-2828.	2.6	326
330	Estimating GFR from serum creatinine concentration: Pitfalls of GFR-estimating equations. American Journal of Kidney Diseases, 2005, 45, 610-613.	2.1	14
331	Home Blood Pressure Monitoring in CKD. American Journal of Kidney Diseases, 2005, 45, 994-1001.	2.1	109
332	Prevalence of Left Ventricular Hypertrophy: Some Alternate Thoughts. American Journal of Kidney Diseases, 2005, 46, 1148.	2.1	3
333	Ironing out the mystery of nephrotoxicity of parenteral iron. Translational Research, 2005, 146, 5-6.	2.4	2
334	Smoking, oxidative stress and inflammation: Impact on resting energy expenditure in diabetic nephropathy. BMC Nephrology, 2005, 6, 13.	0.8	58
335	On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. American Journal of Physiology - Renal Physiology, 2005, 288, F265-F271.	1.3	23
336	Correlates of Systolic Hypertension in Patients With Chronic Kidney Disease. Hypertension, 2005, 46, 514-520.	1.3	115
337	Hypertension in Chronic Kidney Disease and Dialysis: Pathophysiology and Management. Cardiology Clinics, 2005, 23, 237-248.	0.9	29
338	Etiology and Management of Hypertension in Chronic Kidney Disease. Medical Clinics of North America, 2005, 89, 525-547.	1.1	16
339	Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrology Dialysis Transplantation, 2005, 20, 135-140.	0.4	37
340	Role of oxidative stress in diabetic nephropathy. Advances in Chronic Kidney Disease, 2005, 12, 146-154.	0.6	93
341	Statin Induced Proteinuria: Renal Injury or Renoprotection?. Journal of the American Society of Nephrology: JASN, 2004, 15, 2502-2503.	3.0	62
342	Scholarly Review. Exploring the paradoxical relationship of hypertension with mortality in chronic hemodialysis. Hemodialysis International, 2004, 8, 207-213.	0.4	18

#	ARTICLE	IF	CITATIONS
343	Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. <i>Kidney International</i> , 2004, 65, 2279-2289.	2.6	218
344	Transferrin saturation with intravenous irons: An in vitro study. <i>Kidney International</i> , 2004, 66, 1139-1144.	2.6	18
345	Comparing loop diuretics in chronic kidney disease. <i>Kidney International</i> , 2004, 65, 337.	2.6	1
346	HYPERTENSION IN HEMODIALYSIS PATIENTS: Hypertension in Hemodialysis: A Comprehensive Review. <i>Seminars in Dialysis</i> , 2004, 17, 249-249.	0.7	2
347	Special Article: Improving Outcomes in CKD and ESRD Patients: Carrying the Torch from Training to Practice. <i>Seminars in Dialysis</i> , 2004, 17, 380-397.	0.7	16
348	Evaluation of Kidney Function in Patients with Acute Renal Failure Using High-Performance Liquid Chromatography: A Case Report. <i>Pharmacotherapy</i> , 2004, 24, 145-149.	1.2	0
349	Oxidative stress in hypertension and chronic kidney disease: role of angiotensin III 1This is a US government work. There are no restrictions on its use.. <i>Seminars in Nephrology</i> , 2004, 24, 101-114.	0.6	84
350	Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (â%¥250) Tj ETQq0 0 0 rgBT JOverlock	2.1	52
351	Ambulatory GFR measurement with cold iothalamate in adults with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 41, 752-759.	2.1	42
352	Liquid chromatography for iothalamate in biological samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 785, 345-352.	1.2	22
353	A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. <i>Kidney International</i> , 2003, 64, 632-640.	2.6	42
354	Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. <i>Kidney International</i> , 2003, 64, 1772-1779.	2.6	97
355	Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. <i>Kidney International</i> , 2003, 63, 217-224.	2.6	93
356	Systolic Hypertension in Hemodialysis Patients. <i>Seminars in Dialysis</i> , 2003, 16, 208-213.	0.7	35
357	Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. <i>American Journal of Medicine</i> , 2003, 115, 291-297.	0.6	416
358	Newly Developed Techniques to Study and Diagnose Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2188-2198.	3.0	81
359	Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, F863-F869.	1.3	107
360	Selection of Initial Antihypertensive Therapy, Regimen Design, and Goal Blood Pressure. <i>Cardiology in Review</i> , 2003, 11, 197-205.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Racial Difference in the Activity of the Amiloride-Sensitive Epithelial Sodium Channel. <i>Hypertension</i> , 2002, 40, 903-908.	1.3	40
362	Issues Related to Iron Replacement in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2002, 22, 479-487.	0.6	30
363	Rapid microplate method for PAH estimation. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F236-F241.	1.3	30
364	Add-on angiotensin II receptor blockade lowers urinary transforming growth factor- β^2 levels. <i>American Journal of Kidney Diseases</i> , 2002, 39, 486-492.	2.1	110
365	Dipstick proteinuria: Can it guide hypertension management?. <i>American Journal of Kidney Diseases</i> , 2002, 39, 1190-1195.	2.1	39
366	Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2002, 40, 924-931.	2.1	26
367	Reply from the author. <i>Kidney International</i> , 2002, 61, 1180-1181.	2.6	2
368	Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. <i>Kidney International</i> , 2002, 61, 1830-1839.	2.6	176
369	Editorials: Assessment of Blood Pressure in Hemodialysis Patients. <i>Seminars in Dialysis</i> , 2002, 15, 299-304.	0.7	44
370	Rapid, fluorimetric liquid chromatographic determination of malondialdehyde in biological samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 775, 121-126.	1.2	243
371	Treatment of Hypertension in Patients with Diabetes: Lessons from Recent Trials. <i>Cardiology in Review</i> , 2001, 9, 36-44.	0.6	9
372	Add-on angiotensin receptor blockade with maximized ACE inhibition. <i>Kidney International</i> , 2001, 59, 2282-2289.	2.6	116
373	Prediction of hypertension in chronic hemodialysis patients. <i>Kidney International</i> , 2001, 60, 1982-1989.	2.6	99
374	Clinical performance characteristics of hemodialysis graft monitoring. <i>Kidney International</i> , 2001, 60, 762-766.	2.6	46
375	Buzz in the axilla: A new physical sign in hemodialysis forearm graft evaluation. <i>American Journal of Kidney Diseases</i> , 2001, 38, 853-857.	2.1	15
376	Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses. <i>American Journal of Kidney Diseases</i> , 2001, 38, 1245-1250.	2.1	73
377	Bedside Hemoglobinometry in Hemodialysis Patients: Lessons from Point-of-Care Testing. <i>ASAIO Journal</i> , 2001, 47, 240-243.	0.9	20
378	Studies of renal injury III: Lipid-induced nephropathy in type II diabetes. <i>Kidney International</i> , 2000, 57, 92-104.	2.6	65

#	ARTICLE	IF	CITATIONS
379	ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. <i>Kidney International</i> , 2000, 58, 2084-2092.	2.6	222
380	Successful Nonsurgical Management of Coronary Artery Perforation Aided by Implantation of a Bare Stent. <i>Journal of Interventional Cardiology</i> , 2000, 13, 45-49.	0.5	0
381	Urinary Protein Binding Does Not Affect Response to Furosemide in Patients with Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1100-1105.	3.0	52
382	Supervised atenolol therapy in the management of hemodialysis hypertension. <i>Kidney International</i> , 1999, 55, 1528-1535.	2.6	91
383	Role of home blood pressure monitoring in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1999, 33, 682-687.	2.1	62
384	Monitoring interposition graft venous pressures at higher blood-flow rates improves sensitivity in predicting graft failure. <i>American Journal of Kidney Diseases</i> , 1999, 34, 212-217.	2.1	9
385	Extrasupport guidewire as primary wire for percutaneous transluminal coronary angioplasty. , 1998, 43, 365-365.		0
386	Long-term outcome of intracoronary microstent implantation: Lesion matched comparison with Palmaz-Schatz stent. , 1998, 43, 397-401.		3
387	Percutaneous balloon aortic valvuloplasty during pregnancy: Use of the Inoue balloon and the physiologic antegrade approach. , 1998, 45, 422-425.		49
388	Chromatographic estimation of iothalamate and p-aminohippuric acid to measure glomerular filtration rate and effective renal plasma flow in humans. <i>Biomedical Applications</i> , 1998, 705, 3-9.	1.7	28
389	Alcohol Therapy for Hypertrophic Cardiomyopathy: Is It Time to Toast?. <i>Circulation</i> , 1998, 97, 2096-2097.	1.6	1
390	More on Predicting Dietary Phosphorus Intake. <i>Journal of the American Dietetic Association</i> , 1997, 97, 583-584.	1.3	5
391	Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. , 1997, 41, 56-58.		15
392	Management of hepatic venous outflow obstruction (Budd Chiari Syndrome): Balloon angioplasty with or without the use of a stent. , 1997, 42, 240-240.		1
393	Inoue balloon valvuloplasty for the tricuspid valve during pregnancy. , 1997, 42, 241-241.		1
394	Technical considerations in deploying the sheathed Palmaz-Schatz stent in distal coronary artery and bypass graft lesions. , 1996, 37, 73-75.		8
395	Management of idiopathic obstruction of the hepatic and suprahepatic inferior vena cava with a self-expanding metallic stent. , 1996, 39, 252-257.		16
396	Stent Placement for Idiopathic Obstruction of the Inferior Vena Cava. <i>Asian Cardiovascular and Thoracic Annals</i> , 1996, 4, 142-145.	0.2	0

#	ARTICLE	IF	CITATIONS
397	Timing of Plasma Exchange Therapy for Thrombotic Thrombocytopenia Purpura: A Brief Clinical Observation. American Journal of the Medical Sciences, 1996, 311, 167-168.	0.4	11
398	In-hospital outcome of percutaneous transluminal coronary angioplasty for long lesions and diffuse coronary artery disease. Catheterization and Cardiovascular Diagnosis, 1995, 35, 294-300.	0.7	9
399	Hematological manifestations of congenital cytomegalovirus infection. Indian Journal of Pediatrics, 1995, 62, 473-477.	0.3	2
400	The Post-Transurethral Resection of Prostate Syndrome: Therapeutic Proposals. American Journal of Kidney Diseases, 1994, 24, 108-111.	2.1	42
401	Heterogeneity in Gentamicin Clearance Between High-Efficiency Hemodialyzers. American Journal of Kidney Diseases, 1994, 23, 47-51.	2.1	23
402	Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology, 1994, 107, 548-571.	0.6	154
403	Subclavian Dialysis Catheter Placement under Sonographic Guidance. Nephron, 1994, 67, 255-255.	0.9	0
404	Effects of cooler temperature dialysate on hemodynamic stability in "problem" dialysis patients. Kidney International, 1993, 44, 606-612.	2.6	95
405	Gentamicin Clearance During Hemodialysis: A Comparison of High-Efficiency Cuprammonium Rayon and Conventional Cellulose Ester Hemodialyzers. American Journal of Kidney Diseases, 1993, 22, 296-299.	2.1	19
406	Chronic Kidney Disease and Hypertension. , 0, , 345-352.		0
407	Advances in the area of cardiorenal medicine: clinical research highlights from selected papers published in NDT. Nephrology Dialysis Transplantation, 0, , .	0.4	1